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1 Introduction 
 
The investigation of inherited diseases is fundamental to medical molecular 
biology. The understanding of the genetic basis and the mechanisms that 
lead to the disturbance of complex biological system brings new insights 
into human biology, as well as assisting in the prognosis and the 
development of treatments of the diseases. 
 
1.1 Ketone bodies of metabolism 
The ketone bodies are: acetoacetate (AcAc), D-β-hydroxybutyrate (βOHB) 
and acetone. They are inevitable part of the energetic metabolism of the 
organism during fasting and starvation, mainly important for the brain and 
heart energy supply. The metabolism of ketone bodies includes ketogenesis 
(synthesis of ketone bodies) and ketolysis (their utilization). Ketogenesis 
primarily occurs in liver. AcAc is synthesized from acetyl-CoA and 
acetoacetyl-CoA, the intermediate of β-oxidation of fatty acids and 
ketogenic amino acids, principally leucine. It is the final phase of lipid 
energy metabolism. The enzymes of ketogenesis include acetoacetyl-CoA 
thiolase (T2), 3-hydroxy-3-methylglutaryl-CoA synthase (HMGS), and 3-
hydroxy-3-methylglutaryl-CoA lyase (HMGL). The utilization of ketone 
bodies occurs in extrahepatic tissues, particularly in brain, kidney, heart and 
skeletal muscle. The enzymes of ketolysis are succinyl-CoA: 3-ketoacid-
CoA transferase (SCOT) and acetoacetyl-CoA thiolase (T2). T2 is active in 
both ketogenesis and ketolysis.1 (Fig.1) 
Abnormal levels of ketone bodies lead to ketosis or to hypoketotic 
hypoglycemia. 
 
1.1.1 3-hydroxy-3-methylglutaryl-CoA lyase (HL) deficiency 
3-hydroxy-3-methylglutaryl-CoA lyase (HL) deficiency is a rare autosomal 
recessive disease. The patients usually present in the first year of life or in 
infancy with acute episodes of vomiting, lethargy, hypotonia, and coma; 
about 20% of cases are fatal.2 Laboratory tests reveal metabolic acidosis, and 
hypoglycemia without ketoaciduria. Urinary organic acid profile includes 
high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 
3-methylglutaconic acid and 3-methylglutaric acid. The treatment is based 
on protein- and fat-free diet, carnitine supplementation and on avoiding 
metabolic stress such as fasting and starvation. If appropriately treated 
without the complications, the illness remit within the aging, and adults are 
free of symptoms. 
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3-hydroxy-3-methylglutaryl-CoA Lyase (HL) (EC 4.1.3.4) catalyzes the 
cleavage of 3-hydroxy-3-methylglutaryl-CoA into acetyl-CoA and 
acetoacetate, the last step of ketogenesis and of leucine metabolism. 
Two isoforms of human HL have been found, mitochondrial and 
peroxisomal.3,4 
The mature human mitochondrial HL is a homodimer that requires the 
presence of divalent cation such as Mg2+, Mn2+ for its catalytic activity. The 
325aa-residue precursor is cleaved to a mature 298aa-residue 31.5-kDa 
monomer.5  
The HMGCL gene maps on chromosome 1p35.1-36.1, spans over 24 kb. 
Nine exons are transcribed into ~1.7 kb mRNA.5 Up to date 28 mutations in 
93 patients have been published. 6 
 
1.1.2 Mitochondrial acetoacetyl-CoAthiolase (T2) deficiency 
Mitochondrial acetoacetyl-CoAthiolase (T2) deficiency (3-ketothiolase 
deficiency, 3KTD) is an autosomal recessive disorder of isoleucine 
catabolism and ketone body metabolism.  
Patients with 3KTD usually present in neonates with the ketoacidotic 
episodes accompanied with infections, vomiting, and dehydration. The 
urinary organic acids profile reveal increased excretion of tiglylglycine, 2-
methyl-3-hydroxybutyrate, and 2-methylacetoacetate, 3-hydroxybutyrate, 
and acetoacetate. The treatment is based on protein-and fat-low diet, 
carnitine supplementation; and glucose administration during acute episodes. 
The prognosis depends on early treatment and avoiding massive ketoacidotic 
episodes.  
Mitochondrial acetoacetyl-CoA thiolase (T2) (EC 2.3.1.9) catalyzes the 
reversible reactions of ketogenesis and ketolysis, and isoleucine catabolism. 
T2 is the only enzyme of ketone bodies metabolism appeared in ketogenesis 
as well as in ketolysis. T2 is activated in presence of K+ ions.1 T2 catalysis 
reactions:  
AcAc-CoA + CoA ↔ 2Ac-CoA 
2MeAcAc-AoA + CoA ↔ Ac-CoA + propionyl-CoA.  
Human T2 427aa-residue precursor is cleaved in mitochondria to 394aa-
residue 41-kDa subunits forming the mature homotetramer. The T2 gene 
ACAT1 is localized on chromosome 11q22.3-q23.1, contains 12 exons and 
spans over 27 kb. The mRNA is about 1.7 kb.7 About 30 disease causing 
mutations in ACAT1 gene were published up to date.8 
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Fig.1: Ketone body metabolism, summarized view. FA = fatty acids, β-ox = 
β-oxidation, T2 = mitochondrial acetoacetyl-CoA thiolase, mHS = mitochondrial 3-
hydroxy-3-methylglutaryl-CoA synthase, HL = 3-hydroxy-3-methylglutaryl-CoA 
lyase, 3HBD = 3-hydroxybutyrate dehydrogenase, SCOT = succinyl-CoA: 3-ketoacid 
CoA transferase, 3HB = R-3-hydroxybutyrate, Lynen cycle = HMG-CoA pathway. 
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1.2 Methylmalonic acidemia 
Methylmalonic acidemia (MMA) is an autosomal recessive inborn error of 
metabolism that results from decreased activity of the enzyme 
methylmalonyl-CoA mutase (MCM, EC 5.4.99.2). MCM catalyzes the 
isomerization of L-methylmalonyl-CoA to succinyl-CoA in the propionate 
pathway. In humans it is involved in the catabolism of amino acids valine, 
isoleucine, methionine and threonine as well as cholesterol and odd-chain 
fatty acids catabolism. MCM is one of two enzymes which require the 
derivate of cobalamin (vitamin B12), adenosylcobalamin (AdoCbl), as its 
cofactor. The other is methionine synthase, with the cofactor, 
methylcobalamin (MeCbl).9 According to blocks in the synthesis of these 
cofactors eight complementation groups (CblA-CblH) have been identified 
through biochemical studies of cell lines from affected patients in vitro. 
Isolated methylmalonic acidemia is caused by a functional defect of the 
apoenzyme (mut forms) or from the insufficiency in three complementation 
groups occurring in the mitochondrion (cblA, cblB and cblH), which does 
not affect synthesis of MeCbl.9 Fig.2 
The onset of the disease is early after birth or during infancy. Patients with 
neonatal form, present with vomiting, lethargy, feeding refusal, muscular 
hypotonia and seizures. If not appropriately treated, patients progress into 
acidotic crisis, respiratory distress and coma. Within a few days patients die 
or develop permanent brain damage. The late onset forms are more variable 
from chronic symptoms as failure to thrive, anorexia, recurrent vomiting, 
and behavioral disturbances to life-threatening episodes of metabolic 
decompensation and severe organ failure. 
During acute episodes of metabolic decompensation a massive accumulation 
of metabolites occurs (e.g. methylmalonic acid, 2-methylcitric acid, 3-
hydroxypropionic acid, and other derivates of propionyl-CoA, and 
ammonia) that lead to intoxication of organism. Homocystinuria is not 
present. The therapy is based on low-protein, high-energy diet and carnitine 
and metronidazole supplementation. Vitamin B12 is used in B12-responsive 
patients. Usually very low cases of mut patients respond to vitamin B12 
supplementation, whereas over 90% of cblA and 40% cblB patients show 
such a response.10,11 The most important for the patients is early diagnosis 
before the metabolic decompensation occurs. 
1.2.1 mut form of MMA 
Methylmalonyl–CoA mutase (MCM) is the mitochondrial nuclear-encoded 
enzyme which catalyzes the interconversion of L-methylmalonyl-CoA and 
succinyl-CoA.  
The human MUT gene is located on the chromosome 6 (6p12-21.1) and 
composed of 13 exons spanning more than 35 kb. Transcript is ~2.7 kb in 
length and encodes propeptide of 750 amino acids. The MCM is targeted 
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into the mitochondrial matrix, where its 32-residue N-terminal leader 
sequence is cleaved.12,13 Human MCM is a homodimer of 78.5 kDa identical 
subunits (α2).14 Each subunit contains 1 mol of an adenosylcobalamin 
cofactor.15 Two biochemical phenotypes have been distinguished in cultured 
fibroblasts: mut0, mutase activity is completely lost, and mut-, residual 
activity is detectable and/or the activity in mut- cells is increased by the 
addition of hydroxycobalamin.16 Over 100 disease causing mutations have 
been already found in MUT gene.8 
 
1.2.2 cblA form of MMA 
cblA form of MMA is caused by the mutations in MMAA gene.17 The gene 
product MMAA shares  67% sequence similarity to MeaB, a 
metallochaperone, member of GTPases subfamily from Methylobacterium 
extorquens.18 MeaB was hypothesized to have a protective function from 
irreversible inactivation of MCM, stabilizing the dimer form of the enzyme 
and/or to protect the bound cofactor from attack by oxygen, water, and 
highly reactive radical intermediates.18-20 
The gene MMAA was localized to chromosome 4q31.1-2, contains 7 exons, 
encompassing 17.1 kb and expressing a ~1.2 kb mRNA, predicting a 
polypeptide of 418 amino acids. The MMAA protein contains a 
mitochondrial targeting sequence and signal cleavage site.17 More than 30 
mutations have been published in MMAA gene up to date.8 
 
1.2.3 cblB form of MMA 
cblB form of MMA is caused by the functional defect in ATP : cob(I)alamin 
adenosyltransferase (ATR).21,22 ATR catalyzes transfer of adenosyl group 
from ATP to cob(I)alamin to form adenosylcobalamin (AdoCbl)23. 
The human ATR gene MMAB maps to chromosome 12q24, contains 9 
exons, comprising an open reading frame (ORF) of 750 bp in length. The 
propeptide of 250 amino acids is targeted by 24 amino acid leader sequence 
to the mitochondrion, where the protein of a molecular weight of 27.3 kDa is 
formed.21,22 About 20 mutations are known in MMAB gene.8 
1.2.4 Correlation of genotype and phenotype 
The typical neonatal form of the disease with an early onset, high mortality 
frequency, and poor neurological outcome occurs in mut0 patients. mut- and 
cblB patients phenotypes vary from severe neonatal forms to milder forms 
with a later onset. B12-nonresponsive cblB patients (about 60%) have the 
same phenotype as mut0 patients contrary to mut- patients, where the B12-
responsivity is not critical to determination of the outcome. The less severe 
forms show cblA patients, who became symptomatic later in infancy and 
have a better survival outcome.10,11 
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Fig.2: The summarized view of Propionate, Methylmalonate and Cobalamin 
metabolism.  
The major catabolic pathway of propionyl-CoA and methylmalonyl-CoA. Propionyl-
CoA carboxylase = PCC (requires biotin as its cofactor and ATP and Mg++ ions), DL-
methylmalonyl-CoA racemase = MCEE, methylmalonyl-CoA mutase = MCM 
(requires AdoCbl as its cofactor). 
Cobalamin pathway. Cobalamin = Cbl, transcobalamin II = TCII, methylcobalamin = 
MeCbl, adenosylcobalamin = AdoCbl. Complementation groups cblA-cblH (in italic) 
- defects in the synthesis of AdoCbl and MeCbl. cblA ~ MMAA protein, cblB ~ ATR 
(ATP : cob(I)alamin adenosyltransferase), cblC ~ MMACHC (predicted protein), 
cblD ~ MMADHC (predicted protein), cblE ~ MTRR (methionine synthase 
reductase), cblG ~ MTR (methionine synthase). 
 
1.3 Contiguous X-linked deletion syndrome 
Contiguous X-chromosome deletion syndrome encompassing the BTK and 
TIMM8A genes leads to atypical clinical course of X-linked 
agammaglobulinemia with neurological impairment, typical for Mohr-
Tranebjaerg syndrome. 
X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency 
caused by a B-cell specific maturation defect24. The affected gene BTK 
(Bruton tyrosin kinase) is located on chromosome Xq22.1, composed of 19 
exons and spanning more than 37.5 kb.25,26 
Mohr-Tranebjaerg syndrome (MTS; dystonia-deafness syndrome, DDS, 
DDP) presents with progressive sensorineural deafness and dystonia.27-29 
The disease gene TIMM8A (originally named DDP1) maps to chromosome 
Xq22 and contains of 2 exons.30 
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The first exon of the cDNA sequence of TIMM8A begins 770 bp 
downstream from the polyadenylation signal of BTK.31 
Chromosome X is rich on interspersed repetitive sequences; especially on 
retrotransposones class LINEs, the L1 family (29 % of chromosome 
sequence)32. The high homology of repetitive sequences may lead to unequal 
homologous recombination resulting in gross deletions.32,33 
 
1.4 Mucopolysaccharidosis type IIIC 
Mucopolysaccharidosis type IIIC (MPS IIIC) is a lysosomal storage disease 
caused by deficiency of enzyme heparin acetyl-CoA: α-glucosaminide N-
acetyltransferase (HGSNAT, EC 2.3.1.78).34 MPSIIIC is a rare autosomal 
recessive disease, which manifests during the childhood with progressive 
neurological degeneration. Patients present first with hyperactivity, sleep 
disorders, behavioral abnormalities, that proceeds to mental retardation, 
hearing loss and convulsions. The visceral manifestation, as 
hepatosplenomegaly and delayed growth, is relatively mild. Most patients 
die before adulthood. The glycosaminoglycans are present in the urine.34 
HGSNAT is the lysosomal membrane enzyme catalysis the N-acetylation of 
the terminal glucosamine residues of heparin sulfate. It is the only non-
hydrolase in the degradation of glycosaminoglycans. Fig.3 
The HGSNAT gene was independently discovered by Hrebicek35 and Fan36 
in 2006. The gene maps on chromosome 8p11.1 and contains 18 exons, 
comprising an ORF of 1,992 bp in length, which encodes a 73-kDa protein.35 
About 43 mutations among over 70 probands have been found in HGSNAT 
gene up to date.36-38 
 
 
 
Fig.3: Reaction catalyzed by heparin acetyl-CoA: α-glucosaminide 
N-acetyltransferase (HGSNAT, EC 2.3.1.78) the step of degradation of heparin 
sulfate. The deficiency in HGSNAT corresponds to mucopolysaccharidosis type IIIC. 
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2 Aims 
 
The main goal of the PhD thesis “Molecular analysis in cases of inherited 
diseases” is to describe various methods, which lead to identification and 
characterization of the mutations in nuclear genes. 
 
The study is divided into three sections with specific aims: 
 
Clinical, biochemical and molecular biological analysis in cases of 
inherited diseases of organic acids metabolism 
• to establish system of differential diagnostic methods for the 
patients with the erorrs of ketone body metabolism and 
methylmalonic acidemia 
• to identify pathogenic mutations in the known disease genes 
(HMGCL, ACAT1, MUT, MMAA, MMAB) in the cohorts of 
patients 
• to perform phenotype - genotype correlation and summarize 
clinical and biochemical symptoms in patients 
 
Characterization of X-linked contiguous syndrome 
• to set up the molecular biological method, which leads to detection 
of gross deletions in hemizygotes 
 
The molecular study of mucopolysaccharidosis type IIIC 
• to map and identify disease gene HGSNAT of monogenic disorder 
MPS IIIC 
• to characterize HGSNAT gene and the protein product acetyl-CoA: 
α-glucosaminide N-acetyltransferase 
to identify pathogenic mutations of HGSNAT gene in the cohort of patients 
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3 Material and Methods 
 
3.1 Biochemical and enzymatic studies 
Metabolite measurements: The metabolites were determined using GC-MS 
for urinary and plasma organic acids 39, MS/MS for acylcarnitines in a dry 
blood spot40, ion exchange liquid chromatography for amino acids in 
blood41, spectrophotometric method for ammonia in plasma42, HPLC with 
fluorescence method for total homocystein in plasma and serum43, 
radiochemical method for carnitine in plasma and serum44 and 
spectrophotometric method for glycosaminoglycans in urine.45 
Enzyme assays: The enzyme activity of 3-hydroxy-3-methylglutaryl-CoA 
lyase was determined by spectrophotometric46 analysis or by HPLC 
method47 in lymphocytes and/or cultured fibroblastes using 3-hydroxy-3-
methylglutaryl-CoA as a substrate and measuring the elevation of 
acetoacetyl-CoA and acetoacetate, respectively. The activity of β-
ketothiolase was measured as decreasing level of the substrate acetoacetyl-
CoA with and without K+ ions by spectrophotometric method1 in cultured 
fibroblasts. Methylmalonyl-CoA mutase activity was measured in the 
presence of 5µmol/l adenosylcobalamin, using L-methylmalonyl-CoA as a 
substrate and detecting the formation of succinyl-CoA by HPLC method 
with UV detection48 in lymphocytes and/or cultured fibroblasts. The enzyme 
activity of N-acetyltransferase was measured using the substrate 4-
methylumbelliferyl β-D-glucosaminide by the fluorogenic method49 in 
lymphocytes and/or cultured fibroblasts. 
 
3.2 Mutation analysis 
Nucleic acid isolation and RT-PCR: Genomic DNA (gDNA) and total RNA 
was isolated from cultured skin fibroblast and/or venous blood using the 
standard protocols.50,51 The total RNA was used for preparation of 
complementary DNA (cDNA) by reverse transcription with SuperScript II 
and Oligo(dT)18 primer (Invitrogen). 
 
PCR amplification and DNA sequencing: The entire coding sequences and 
all exons with their intron boundaries of the investigated genes (except 
exons of ACAT1 gene) were PCR amplified employing cDNA and gDNA, 
respectively, as a template. The PCR products were directly sequencing on 
an ALF Express DNA sequencer (Pharmacia) or on an ABI 3100-Avant 
DNA Analyzer (Applied Biosystems). 
Confirmation of mutation and cis/trans position: The presence of some 
mutations was verified by ARMS method or PCR/RFLP method using 
cDNA and/or gDNA as a template. The trans position of most mutations was 
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verified by investigation of parents samples or by dividing the allels by 
cloning the PCR products into the pCR4-TOPO TA vector (Invitrogen). 
 
3.3 Analysis of gross deletion using PCR probes                                
The extent of the deletions were analyzed by inspection of presence or 
absence of PCR products in hemizygote patients and control genomic DNA. 
Sixteen PCR probes were designed in the region of BTK gene, TIMM8A 
gene and TAF7L gene according to the reference sequence in GenBank 
(accession no. NC_000023.9). Specificity of the probes was verified by 
direct sequencing. 
 
3.4 Genotyping and linkage analyses 
The samples of five patients from four unrelated families and their 49 
relatives were genotyped for 18 microsatellite markers in an 18.7-cM region. 
The region on chromosome 8 included previously published 8.3-cM 
candidate region.52 The genotyping was performed on LI-COR IR2 
sequencer by use of Saga genotyping software (LiCor).53 Genotypes were 
screened for errors by use of the Ped Check Program. The linkage analysis 
was performed using a codominant model based on the measurement of 
enzyme activity of N-acetyltransferase. The values of enzyme activities 
distinguished between the affected probands, carriers and the health 
individuals. For the multipoint linkage analysis was used program Allegro 
1.2c.54 
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4 Results and discussion 
 
4.1 Clinical, biochemical and molecular biological 
analysis in cases of inherited diseases of organic 
acids metabolism 
4.1.1 Metabolism of ketone bodies 
From the cohort of 39 children with ketosis, who were differentially 
diagnosed on biochemical and enzymological level, only one patient was 
revealed with the defect in ketolysis; the deficit of 3-ketothiolase (3KTD). 
Three patients with hypoketotic hypoglycemia were diagnosed with a defect 
in ketogenesis, 3-hydroxy-3-methylglutaryl-CoA lyase (HL) deficiency. In 
these four cases (one 3KTD deficiency and three HL deficiency) molecular 
analysis was performed. The molecular analysis was further performed for 
two patients from Austria and one patient from Germany with HL 
deficiency. 
4.1.1.1 Molecular analysis in patients with HL deficiency 
Molecular analysis revealed all patients as carriers of mutations in HMGCL 
gene. Summarized results of all patients with HL deficiency examined in our 
laboratory are in Table. 1 
Two missense mutations p.R41Q and p.H233R and one novel deletion 
p.R10fs (originally named p.P9fs(-1)) were found in Czech patients. Another 
missense mutation p.D42E and one deletion p.F305fs were found in two 
Austrian patients. 
The German patient is heterozygous for a novel mutation: The substitution 
c.252G>A does not alter the amino acid residue p.Q84Q, but affects the 
donor splice-site in exon 3 (AG/gt). The latter mutation was not detected in 
any exon and exon/intron boundaries of HMGCL gene. The analysis of RT-
PCR products suggests presence of two splicing mutations: c.252G>A, 
which lead to skipping of exon 3, and predicted intronic mutation, which 
leads to the skipping exon 2 and probably skipping of exons 2 plus exon 3. 
A novel mutation p.R10fs (c. 27delG) in the first exon, leads to a frame shift 
and premature stop codon after 32 amino acid residues. We predict the 
mutation as disease-causing, because it affects the HL ORF. This frame shift 
mutation does not lead to nonsense mediated decay (NMD) - the degradation 
of mRNA 
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Tab. 1 Mutations in HMGCL gene in patients with HL deficiency 
Family 
no. Origin Allele 1 
(predicted 
effect 
on protein) Allele 2 
(predicted 
effect 
on protein) 
1 Czech c.698A>G p.H233R c.698A>G p.H233R 
2 Czech c.698A>G p.H233R c.27delG p.R10GfsX24
#
 
3 Czech c.122G>A p.R41Q c.122G>A p.R41Q 
4 Austria c.126G>T p.D42E c.126G>T p.D42E 
5 Austria c.913_915delTT p.F305YfsX10
##
 c.913_915delTT p.F305YfsX10
##
 
6 Germany 
c.252G>A;  
r.145_252del
$
 p.N49_Q84del 
r.61_144del; 
r.61_252del
$$
 
p.V21_K48del; 
p.V21_Q48del 
 
$ the exonic mutation c.252G>A does not change the amino acid residue p.Q84Q, but leads to 
skipping of exon 3 r.145_252del (p.N49_Q84del) 
$$ the predicted intronic mutation leading to skipping of exon 2 r.61_144del (p.V21_K48del) and 
probably to skipping of exon 2 plus exon 3 (p.V21_Q48del) 
# mutations p.R10GfsX24 and ## p.F305YfsX10, were originally named p.P9fs(-1) and p.F305fs      
(-2), respectively 
 
4.1.1.2 Molecular analysis in patient with 3KTD  
The first case of, 3-ketothiolase deficiency, an error in ketolysis was 
revealed by differential diagnosis in Czech Republic.(ref) The molecular 
analysis revealed compound heterozygosity for two novel mutations 
p.M193T (c.578T>C) and p.I347T (c.1040T>C). The expression analysis of 
both novel mutations was performed by Fukao and confirmed the disease 
causing effect of these mutations. Both amino acids residues are well 
conserved. Mutation p.M193T in exon 6 probably affects the CoA binding 
site, important for the liver specific T2 thiolase. Even exonic mutation 
c.578T>C occurs at the splice-site of exon 6 (TG/gt), it likely does not alter 
the correct splicing of mRNA. Mutation p.I347T in exon 11 probably 
influences the catalytic site of the enzyme. 
 
4.1.2 Methylmalonic acidemia 
The cohort of 14 patients from 13 unrelated families (two patients were 
twins) from the region of former Czechoslovakia were diagnosed with 
methylmalonic acidemia (MMA) in The Institute of Inherited Metabolic 
Diseases. 
Patients were admitted with the typical symptoms of MMA and the routine 
biochemical testing revealed high levels of methylmalonic acid, methylcitric  
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Tab.2  Biochemical, enzymological and molecular biological results in  
 
patient no. 1 2 3 4 5 6 7 
complementation group cblA cblA cblB cblB cblB mut mut 
 Clinical presentation 
present age  [years] 7 y 3 y 9 y 6 y 8 m 15 y 7† 
age of onset 6 m 5 m 2 d 5 m 3 d 1 d 3 w  
sex F F F F M M F 
B12 responsivity yes yes no no no no no 
Metabolites in urine * 
methylmalonic acid  
4 401 ↑↑↑ 1 914 ↑↑↑ 5800 ↑↑↑ 9 568 [mmol/mol creat.] 
3-hydroxypropionic acid   
148 ↑ 271 ↑↑ 327 ↑↑ 203 [mmol/mol creat.] 
methylcitric acid  
84 ± 43 ↑↑ 217 ↑↑ 210 [mmol/mol creat.] 
Metabolites in plasma * 
methylmalonic acid [μmol/l] 177 not done 356 not done 1328 not done 881 
ammonia [μmol/l] 122 79 224 117 896 216 236 
total homocysteine [μmol/l] 7.6 not done 6.3 3.8 11.9 not done 3.3 
Enzyme assay** 
total mutase in lymphocytes  2.29 not done 2.36 not done not done nd nd 
total mutase in cultured 
fibroblasts  3.61 5.55 3.09 5.82 2.53 not done nd 
Molecular analysis 
gene MMAA MMAA MMAB MMAB MMAB MUT MUT 
allele 1 c.551dupG 
c.592_595 
delACTG c.556C>T c.556C>T c.556C>T c.655A>T c.1106G>A 
(predicted effect on protein) (C184YfsX3) (T198SfsX6) (R186W) (R186W) (R186W) (N219Y) (R369H) 
exon 3 4 7 7 7 3 6 
allele 2 c.551dupG 
c.592_595 
delACTG 
c.557_559 
delGGinsC c.556C>T c.577G>A c.2179C>T c.1105C>T 
(predicted effect on protein) (C184YfsX3) (T198SfsX6) (R186PfsX28) (R186W) (E193K) (R727X) (R369C) 
exon 3 4 7 7 7 13 6 
nd - not detectable, # the twin brother of patient no.11, we suggest the same molecular results 
* laboratory findings during the first attack of disorder, $ except patients 12 and 13 who were 
diagnosed at age of 13 and 8 months, respectively 
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patients with MMA 
 
8 9 10
#
 11 12 13 14 controls 
mut mut mut mut mut mut mut   
  
5 y † 9 m † 16 d † 6.5 y 15.5 y 20 y 2 y   
3 d 2 d 2 d 2 d 1 - 2 m 3 m 5 d 
F F M M M M F 
no no no no no ? no   
  
17 414 6 219 6 219 7 463 ↑↑↑
$
 ↑↑↑
$
 1832 < 14 
251 371 293 212 ↑↑
$
 ↑↑
$
 117 < 19 
61 64 147 65 ↑↑
$
 ↑↑
$
 144 < 8 
  
1 788 975 750 898 not done ↑↑
$
 2149 nd 
500 2 400 279 218 215
$
 not done 4600 < 80 
9.6 4.2 5.6 5.3 not done not done 3.8 < 12.0 
  
nd not done 
not 
done nd not done not done not done 
1.32 - 
2.62 
nd nd 
not 
done not done nd not done nd 
2.31 - 
6.18 
  
MUT MUT MUT MUT MUT MUT MUT   
c.655A>T c.607G>A # c.655A>T c.1105C>T 
c. 2080 
C>T  c.655A>T 
(N219Y) (G203R) # (N219Y) (R369C) (R694W) (N219Y) 
3 3 # 3 6 12 3 
c.1881T>A 
r.546_911del; 
r.754_911del # c.1881T>A c.1156C>A 
c. 2080 
C>T 
r.546_911del; 
r.754_911del 
(H627Q) 
(p.S183_R304del; 
p.H252VfsX22) # (H627Q) (H386N) (R694W) 
(p.S183_R304del; 
p.H252VfsX22) 
11   # 11 6 12   
** total methylmalonyl Co-A mutase activity estimated in the presence of 5 μmol/l 
adenosylcobalamin in nmol of created succinyl-CoA in min on mg of protein 
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acid, and 3-hydroxypropionic acid in urine, and normal concentration of 
homocysteine in plasma. 
The nonradioactive enzyme assay distinguished patients with mut form 
MMA and patients suspected of the cbl forms of MMA. Patients with 
undetectable MCM activity were examined for the mutations in MCM 
apoenzyme MUT gene, whereas patients with MCM activity restored in the 
presence of AdoCbl were examined for mutations in MMAA and/or MMAB 
gene, respectively. On the basis of molecular analysis we were able to 
perform prenatal diagnosis in affected families. The results of biochemical, 
enzymological and molecular biological analysis are summarized in Table 2. 
 
4.1.2.1 Molecular analysis 
 
Mutations in MUT gene 
Seven missense mutations, one nonsense mutation and one splicing mutation 
were found in MUT gene in eight patients with mut form of MMA. Four 
missense mutations p.G203R, p.N219Y, p.R369H and p.R369C, and 
nonsense mutation p.R727X have been previously reported and associated 
with mut0 biochemical phenotype.55-58 Another missense mutation p.R694W 
was associated with mut- biochemical phenotype.58,59 Mutation p.N219Y 
was found in 4 alleles from 16 alleles investigated. The high occurrence 
(25% of alleles) in Czech and Slovak patients corresponds to the high 
frequency of this mutation in Caucasian population, where represents about 
20% of tested alleles.55 
Two novel missense mutations p.H386N (c.1156C>A) and p.H627Q 
(c.1881T>A) were found. The prediction program SIFT60 does not allow any 
alternative amino acid at position 386. Two different mutations were 
previously found in codon 627: p.H627R and p.H627N, respectively. 56,61 
Mutation p.H627R was associated with mut0 biochemical phenotype.56 
A novel heterozygous splicing mutation was detected at the RNA level in 
two cases. Mutations were not detected in exons 2-13 and exon/intron 
boundaries in the MUT gene. The predicted intronic mutation leads to two 
truncated transcripts; skipping of exon 4, and skipping part of exon 3 plus 
exon 4. 
The very close proximity of some mutations in MUT gene and their 
occurrence often in patients of very different backgrounds, (namely 
mutations p.R369H, p.R369C, p.R727X, p.H627Q and p. G203R) suggest 
the presence of mutational hotspots at these locations.57 
Mutations in MMAA gene 
Two frame shift mutations p.C184fs and p.T198fs were found in two cbl 
patients in MMAA gene. Both mutations were homozygous and lead to a 
frame shift. Mutation p.T198fs was already published.17 Mutation p.C184fs 
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(c.551dupG) is novel and lead to a premature stop codon at amino acid 
position 186. The transcripts are not sensitive to NMD. 
Mutations in MMAB gene 
Three patients were diagnosed as cblB. All mutations found in MMAB gene 
are localized in exon 7. Two missense mutations p.R186W and p.E193K 
were already published.21,62 The missense mutation p.R186W is the most 
common mutation in population of European descent (about 30%). Dobson 
et al. first reported p.R186W as potential rare polymorphism, because it was 
present in 4 of 240 alleles in control samples.21 None of 300 control alleles 
examined in Czech samples, did not carry this mutation. The high 
occurrence in different ethnic backgrounds can be explained by the presence 
of CpG dinucleotide, a mutational hotspot. A novel indel mutation p.R186fs 
(c.557_559delGGinsC) is the first insertional-deletional mutation found in 
MMAB gene. Mutation leads to a frame shift and premature stop codon at 
position 213. 
Phenotype - genotype correlation 
Seven of nine patients with MCM apoenzyme deficit presented in the first 
days or weeks of life. Four are deceased and two patients in which the 
disease had severely progressed. All these patients were heterozygous for at 
least one previously reported mutation associated with mut0 biochemical 
phenotype. Two patients, a deceased female (no.8) and the twin brother 
(no.11) of the deceased male (no.10) were heterozygous for the same 
mutations p.N219Y/p.H627Q; we assume the same genotype in both twin 
brothers. Regarding the severity, progression of the disease, as well as nature 
and position of a novel mutation, we predict the mutation p.H627Q is 
assigned with a mut0 class.  
The heterozygous patient p.R369H/p.R369C died at five years of age, which 
correlates with the published mut0 biochemical phenotype of the mutations. 
Two patients, a deceased female and a patient with a serious progression of 
the disease, were heterozygous for a novel splicing mutation and described 
mut0 mutations p.G203R and p.N219Y, respectively. The splicing mutation 
was assigned to the mut0 class. 
The heterozygous patient p.N219Y/p.R727X (no. 6) with an early onset of 
the disease, in the first day of life, is now 15 years old. Both mutations are 
biochemically associated with mut0 phenotype.57 Despite this, the patient’s 
condition is mild. 
The heterozygous patient for known mutation p.R369C (mut0 phenotype) 
and a novel mutation p.H386N is 15 years old with the mild progression of 
the disease. We predict the novel mutation p.H386N to be assigned with 
mut- class. 
The oldest patient in our cohort, a 20 years old male, presents with a 
relatively mild clinical phenotype. It correlates with the known homozygous 
mutation p.R694W that is associated with mut- biochemical phenotype.58,59 
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Both cblA patients present with a mild clinical phenotype and progress well. 
On the contrary, all three cblB patients presented with a serious course of the 
disease. The nature of all mutations found in cblB patients, suggest a poor 
prognosis. 
Cobalamin response was observed in both cblA patients; in one mut- case 
(no.13) we have observed marked improvement with therapy, however, we 
were not able to unambiguously connect these findings with B12-medication 
or with general metabolic compensation. None of mut0 and cblB patients and 
one mut- patient (no.12) were B12-responsive. This correlates with previously 
reported data about B12-response in patients with MMA.10,11 
 
4.2 Characterization of X-linked contiguous syndrome 
The gross deletion on X-chromosome encompassing BTK gene and TIMM8A 
gene were examined in six cases with X-linked agammaglobulinemia with 
neurological problems.  
Sixteen PCR probes were used to determine the extent of deletion in five 
cases. The deletion in all five patients included part of BTK gene and whole 
TIMM8A gene; TAF7L gene, which lies 93 kb centromerically of the first 
exon of the BTK gene, was presented. The results are in Fig.4. 
The extent of deletion in 6th patient was performed in USA by ligation-
mediated PCR; deletion was 196 kb in length and included genes BTK, 
TIMM8A, TAF7L and DRP2. 
Eighty percent of the BTK and TIMM8A genes consist of interspersed 
repeats, mainly Alu and L1 family. The high sequence identity between 
repetitive sequences may lead to unequal homologous recombination33,63,64, 
resulting in gross deletions, duplications or inversions. We suggest that the 
gross deletion in patients with X-contiguous syndrome encompassing BTK 
and TIMM8A genes is caused by unequal homologous recombination 
between repetitive sequences. 
 
 
Fig.4 Extent of deletion in patients 1-5. Pinheads depict sixteen PCR probes, Arrows 
show position and direction of transcription of genes BTK, TIMM8A and TAF7L. The 
lines depict the extent of deletion (patients 1&2 - 30 kb, patient 3 - 16-25 kb, patients 
4&5 - 15-18 kb), a dark part of lines in patients 3-4 shows boundaries of deletion.  
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4.3 The molecular study of mucopolysaccharidosis 
type IIIC 
Mucopolysaccharidosis type IIIC (MPS IIIC) is caused by the mutations in 
HGSNAT gene.35,36 To the identification of this gene lead three 
complementary approaches: narrowing locus for MPS IIIC by linkage 
analysis, bioinformatic search and gene-expression analysis. 
4.3.1 Linkage analysis 
The linkage analysis in four Czech families affected by MPS IIIC was 
performed by use of an autosomal codominant model based on biochemical 
factors. The enzyme assay, measurement of acetyl-CoA: α-glucosaminide N-
acetyltransferase (HGSNAT) activity, distinguished between affected 
carriers and unaffected individuals in the pedigrees. The enzyme activity 
increased in the informative cohort from 5 to 49 individuals (four 
measurements were not informative). Eighteen STR (short tandem repeats) 
markers were used to narrowed interval on chromosome 8 to 2.6-cM, 
between markers D8S1831 and D8S1051. The maximum LOD score was 
7.8 at marker D8S531. The candidate region contains 32 known or predicted 
genes and ORFs. 
4.3.2 Identification of HGSNAT gene 
The HGSNAT gene, originally named TMEM76, was identified on the basis 
of biochemical properties of N-acetyltransferase. Ausseil suggested N-
acetyltransferase as an oligomeric transmembrane glycoprotein, ~ 100-kDa 
polypeptide with an enzyme active site.65 It corresponded to a predicted 
TMEM76 gene product, a ~73-kDa protein with multiple transmembrane 
domains and glycosylation sites. The gene-expression analysis of all 32 
genes located in the candidate region was performed using oligonucleotide-
based microarray assay in two patients with MPS IIIC and four controls. 
Only TMEM76 revealed statistically significant decreased level of transcript 
in patients’ samples compared to controls. The molecular analysis of all five 
Czech patients with MPS IIIC revealed pathogenic mutations in TMEM76 
gene. The further functional expression studies of human TMEM76 and the 
murine ortholog Hgsnat in the fibroblast cell line from a patient with MPS 
IIIC, verified TMEM76 as the disease causing gene of MPS IIIC. 
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Tab.3  Mutations in HGSNAT in patients with MPS IIIC 
family. 
patient Origin allele 1 
predicted effect 
on protein 
exon/ 
intron allele 2 
predicted effect 
on protein 
exon/ 
intron 
1.1 Czech 
c.1118-
1133del16 p.I373SfsX5 11 c.1600C>T p.R534X 15 
2.1 Czech c.1046T>G p.L349X 10 c.1529T>A p.M510K 14 
3.1 Czech c.935+5G>A p.F313XfsX1 9 c.1234C>T p.R412X 12 
3.2 Czech c.935+5G>A p.F313XfsX1 9 c.1234C>T p.R412X 12 
4.1 Czech c.1115G>A p.R372H 11 c.1796C>T p.P599L 17 
5.1 Belorussia c.311G>T p.C104F 2 ? ? 
6.1 Turkey c.1810+1G>A p.S567NfsX14 17 c.1810+1G>A p.S567NfsX14 17 
6.2 Turkey c.1810+1G>A p.S567NfsX14 17 c.1810+1G>A p.S567NfsX14 17 
7.1 Turkey g.124_2462del
$
 del promotor_exon1 g.124_2462del
$
 
del 
promotor_exon1 
8.1 Turkey g.124_2462del
$
 del promotor_exon1 g.124_2462del
$
 
del 
promotor_exon1 
9.1 USA c.1706C>T p.S569L 17 c.202+1G>A # 1 
9.2 USA c.1706C>T p.S569L 17 c.202+1G>A # 1 
9.3 USA c.1706C>T p.S569L 17 c.202+1G>A # 1 
10.1 Germany/Turkey c.1334+1G>A # 12 c.1334+1G>A # 12 
11.1 Germany/Turkey c.1234C>T p.R412X 12 c.1234C>T p.R412X 12 
12.1 Germany c.1114C>T p.R372C 11 c.1114C>T p.R372C 11 
13.1 Germany c.1541G>A p.G514E 14 c.1541G>A p.G514E 14 
14.1 Germany/Turkey c.932C>T p.P311L 9 c.932C>T p.P311L 9 
15.1 Germany c.494T>C p.L165P 4 c.1637C>T p.S546F 16 
16.1 Greece c.1706C>T p.S569L 17 c.1351_1355dupG p.I453HfsX45 13 
17.1 Greece c.1495G>A p.E499K 14 c.1351_1355dupG p.I453HfsX45 13 
18.1 GB c.1626+4dupA  # 15 c.1758C>G  Y586X  17 
19.1 GB/Pakistan c.828-2A>G # 7 c.828-2A>G # 7 
$ the boundaries of gross deletion 2339 bp were assigned according to the gDNA 
sequence from GenBank accession number NC_000008.9 (CON 03_MAR_2008) 
Region: 43112749_43177127 
# the predicted splicing mutation; cDNA sequencing was not done 
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4.3.3 Molecular analysis of the patients with MPS IIIC 
Twenty three patients with MPS IIIC from 19 unrelated families were 
diagnosed on the molecular level in The Institute of Inherited Metabolic 
diseases up to date. Summary of mutations found is in Table3.  
All Czech patients and both Greek patients were compound heterozygotes, 
verified by examination of parents’ samples. In the other cases the parents’ 
samples were not available; we cannot exclude the gross deletion in 
homozygote patients on one allele. In one case only one heterozygous 
mutation was found in gDNA. 
Four nonsense, 11 missense, two predicted frame shift mutations, 6 intronic 
splice-site mutations and one gross deletion were identified in HGSNAT 
gene. 
The nonsense mutation p.R412X was found in 15 alleles by now in patients 
of various ethnic backgrounds.37,38 The Arg 412 involves CpG dinucleotide, 
the known mutational hotspot. We suggest that this mutation has occurred 
more than once in human history. 
All eleven missense mutations affect highly conserved residues. 
Two mutations, one 16 bp deletion and one duplication, lead to the frame 
shift and premature codon. 
Six intronic mutations were found in the donor or acceptor splice sites. In 
two cases the examination of cDNA showed the presence of the abnormal 
transcript. In other four cases, the cDNA was not available, despite this, 
character and location of the nucleotide changes and according to prediction 
programs,66,67 we suggest these mutations affect the splice site and lead to 
the abnormal transcripts. 
One gross deletion was found in two homozygous patients. The deletion is 
2339 bp in length and includes the first exon and the predicted promotor 
region. However, the RT-PCR product, including exons 2 - 18, was 
amplified in both cases. We suggest existence of alternative promotor in 
intron 1.68,69 
4.3.4 Characterization of HGSNAT gene and HGSNAT protein 
The HGSNAT gene contains 18 exons and spans over 62 kb. The RT-PCR of 
the 5’-UTR of the transcript in control samples extended the beginning of 
the transcript at least by 55 nucleotides, compared to GenBank reference 
sequence NM_152419.2. It extends the ORF by 84 nucleotides to 1,992 bp 
in length. The translated predicted polypeptide is thus 28 amino acids longer 
than in GenBank reference sequence NP_689632.2. 
The RT-PCR of total RNA from lymphocytes, cultured skin fibroblasts and 
skeletal muscle revealed three transcripts, one containing the full ORF 
sequence and two shorter; in one case skipping of exons 9 and 10, which 
lead to in-frame deletion of 64 aa residues, and in the second case exons 3, 9 
and 10 were spliced out. We suggest both transcripts do not encode the 
24 
 
active enzyme. The predicted protein HGSNAT contains 11 transmembrane 
domains, four glycosylation sites and 47 residues long signal peptide. The 
only confirmed ortholog is murine Hgsnat; but it was predicted also in four 
other species (rat, bovine, dog and chimpanzee), HGSNAT is highly 
conserved. However, the HGSNAT protein does not show homology to any 
known N-acetyltransferase, even the predicted domains do not show any 
similarity to any known functional domains. We suggest, the predicted 
protein HGSNAT is a member of a new enzyme family. 
At the same time as Hrebicek et al.35 released these data; another group 
published the same results based on proteomic analyses.36 
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5 Conclusions 
 
 
1) The complex system of biochemical, enzyme assays, and molecular 
methods for differential diagnostics was implemented for the patients 
with inborn errors of ketone bodies and methylmalonic acidemia. 
The correct early diagnosis leads to setting the appropriate therapy and 
thereby prevents the progression of patient’s condition. 
The development of molecular methods to confirm the biochemical and 
enzymological results assisted in a course of suitable therapy and prognosis 
in each individual patient. Last but not least, the molecular analysis assisted 
in the early prenatal diagnosis in affected families.  
 
2) The molecular analysis of patients with X-linked 
agammaglobulinemia showed the gross deletion on chromosome X 
encompassing BTK and TIMM8A genes in five cases and another two 
genes TAF7L and DRP2 in one case. The genetic mutation corresponds to 
clinical course of the disease. The investigation of the locus revealed that the 
possible cause of the deletion may be by unequal homologous recombination 
between interspersed repetitive sequences. 
The method of PCR probes is simple and inexpensive and was developed to 
detect the gross deletions in hemizygotes and homozygotes.  
 
3) The novel gene HGSNAT was identified using three complementary 
approaches, linkage analyses, bioinformatic methods and gene-expression 
studies. The mutations in HGSNAT gene lead to mucopolysaccharidosis type 
IIIC, the lysosomal storage disease. MPS IIIC was the last of the lysosomal 
enzymopathies, in which the disease causing gene was not known. 
The molecular analysis and deduced amino acid sequence showed that the 
protein HGSNAT (lysosomal N-acetyltransferase) most likely belongs to a 
new structural class of proteins. 
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7 Abbreviations 
 
aa  amino acid 
3KTD   3-ketothiolase deficiency 
AcAc  acetoacetate 
AdoCbl  adenosylcobalamin 
ARMS  amplification refractory mutation system 
ATR  ATP : cob(I)alamin adenosyltransferase 
DDP, DDS  dystonia-deafness syndrome 
FA  fatty acids 
HGSNAT heparin acetyl-CoA: α-glucosaminide N-
acetyltransferase 
HL  3-hydroxy-3-methylglutaryl-CoA lyase 
LINEs  long interspersed elements 
MCM  methylmalonyl-CoA mutase 
MeCbl  methylcobalamin 
MMA  methylmalonic acidemia/aciduria 
MPS IIIC mucopolysaccharidosis type IIIC 
MTS  Mohr-Tranebjaerg syndrome 
NMD  nonsense mediated decay 
ORF  open reading frame 
PCR  polymerase chain reaction 
RFLP  restriction fragment length polymorphism 
RT-PCR  reverse transcriptase PCR  
STR  short tandem repeats 
T2  mitochondrial acetoacetyl-CoA thiolase 
XLA  X-linked agammaglobulinemia 
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